CSI Market
Sign In | Register

Protagonist Therapeutics inc (PTGX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PTGX quarterly Cash Flow →
From Protagonist Therapeutics inc through Dec 31 2021, changes in Dec 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-130.15
Depreciation & amortization1.28
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation45.97
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Amortization Of Premium On Available For Sale Securities-
Fair Value Adjustment Of Tranche Liability-
Increase Decrease In Operating Lease Liability-
Amortization Of Debt Issuance Costs And Debt Instrument Accretion Of Final Payment Fee-
Increase Decrease In Contract With Customer Liability-21.02
Non Cash Lease Expense1.59
Increase Decrease In Receivables From Collaboration Partner164.88
Increase Decrease In Contract With Customer Asset-
Proceeds From Lease Payments-
Operating Lease Payments-0.90
Income taxes-2.70
Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments, Total0.00
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities4.58
Increase (Decrease) in Accounts Payable, Trade3.72
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.36
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-7.22
Discontinued operations0.00
Net Cash flow from Operating Activities57.67
Investing Activities
Capital Expenditures-1.59
Sale of Capital Items0.00
Short-term Investments Proceeds498.84
Payments to Acquire Available-for-sale Securities, Debt-546.59
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-49.33
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock23.34
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-97.47
Proceeds From Issuance Of Redeemable Convertible Preferred Stock Upon Exercise Of Preferred Stock Warrant Liability-
Cash Cash Equivalents Restricted Cash and Restricted Cash Equivalents-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents97.47
Proceeds From Issuance Public Offering Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs-
Shares Withheld For Net Settlement Of Tax Withholding Upon Vesting Of Restricted Stock Units-0.48
Proceeds From Exercise Of Warrants In Exchange For Issuance Of Pre Funded Warrants-
Issuance Costs Reversals Related To Prior Period Common Stock Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities22.86
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow56.08
Total Cash Flow31.20
4 historic quarters locked

Sign in to unlock the full Protagonist Therapeutics inc cash flow history.

Sign In Create Free Account

About Protagonist Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-019696

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License